A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

NCT05271279 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Research and development strategy adjustment

Conditions

Advanced Solid Tumor
Relapsed/Refractory Lymphoma

Interventions

BIOLOGICAL: OVV-01 Injection+IBR900 Cell Injection

Sponsor

Beijing Boren Hospital